Related Experiment Video

Updated: Aug 11, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy

Kohji Takara1, Toshiyuki Sakaeda, Katsuhiko Okumura

  • 1Department of Hospital Pharmacy, School of Medicine, Kobe University, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.

Current Pharmaceutical Design
|February 4, 2006
PubMed

Insights

Multidrug resistance (MDR) in cancer chemotherapy is a major hurdle. Targeting MDR1/P-glycoprotein, a key transporter protein, offers strategies to overcome this resistance and improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Anticancer drug resistance significantly hinders chemotherapy efficacy.
  • Multidrug resistance (MDR) involves resistance to various drugs, even those not used in treatment.
  • Overexpression of transporter proteins, like MDR1/P-glycoprotein, is a key mechanism in chemoresistance.

Purpose of the Study:

  • To review the current understanding of MDR1/P-glycoprotein.
  • To explore strategies for modulating MDR by targeting MDR1/P-glycoprotein.
  • To summarize advancements in reversing MDR1/P-glycoprotein-mediated resistance.

Main Methods:

  • Literature review of existing research on MDR1/P-glycoprotein.
  • Analysis of clinical investigations on MDR1/P-glycoprotein overexpression.
  • Summary of developed compounds and techniques for MDR reversal.

Main Results:

  • MDR1/P-glycoprotein overexpression is linked to poor chemotherapy outcomes.
  • Inhibition of MDR1/P-glycoprotein function and suppression of its expression are key therapeutic strategies.
  • Various compounds and techniques show potential for reversing MDR.

Conclusions:

  • MDR1/P-glycoprotein is a critical factor in chemotherapy resistance.
  • Targeting MDR1/P-glycoprotein presents promising avenues for overcoming MDR.
  • Further research into MDR1/P-glycoprotein modulation is essential for improving cancer treatment.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mismatch Repair01:36

Mismatch Repair

Overview
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...